Advanced Gastric Cancer
Conditions
Brief summary
This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules combined with chemotherapy and anti-PD1/PDL1 therapy in the advanced gastric cancer.
Interventions
FMT Capsules in Combination with Chemotherapy and Anti-PD1/PD-L1 Therapy
PROCEDUREPlacebo
Mainly composed of starch, the appearance, shape, color, and size are exactly the same as FMT capsules
Sponsors
Changhai Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Voluntarily participate in this study and provide written informed consent. Age ≥ 18 years , male or female. Pathological confirmed locally advanced, unresectable or metastatic gastric adenocarcinoma, esophagogastric junction adenocarcinoma. Able and willing to provide tumor tissue. At least one measurable extracranial target lesion according to iRECIST. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. Life expectancy ≥3 months.
Exclusion criteria
Presence of absolute contra-indications to FMT administration:Toxic megacolon;Inflammatory bowel disease;Anatomic contra-indications to colonoscopy;Colectomy Patient is currently participating and receiving other study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of this study intervention. Currently under any form of systemic antibiotics. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (\> 10 mg prednisone daily or equivalent) or any other form of immunosuppressive therapy two weeks prior to trial treatment. Patients receiving systemic steroids at physiologic doses are permitted to enroll assuming steroid dose is not above the acceptable threshold (\> 10 mg prednisone daily or equivalent). Severe anaphylactic reaction to any food (food allergies). Had a severe hypersensitivity reaction to propofol. Has serious concomitant illnesses. The eligibility can be granted by the treating investigator on individual bases. Has HIV infection or AIDS-related illness. Has active infection of HAV, HBV or HCV. Patients with a history of Hepatitis B/C infection who have received anti-viral therapy and are disease free may be considered for enrollment after discussion with Principal Investigator. Patient has received a live vaccine within 4 weeks prior to the first dose of treatment. Seasonal influenza vaccines or COVID-19 vaccines for injection are generally inactivated virus vaccines and are allowed. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. Females who are pregnant or breastfeeding. Active central nervous system (CNS) metastases and/or leptomeningeal involvement
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Disease Control | up to 6 months | Rate of Disease Control is defined as the percentage of subjects who had a complete response (CR), partial response (PR), or stable disease (SD), as defined by ir-RECIST v1.1. |
| Objective response rate (ORR) | up to 6 months | ORR is defined as the percentage of subjects who had a complete response (CR) or partial response (PR), as defined by ir-RECIST v1.1, and is based on the best response obtained. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | up to 2 years | The length of time (in days) from study intervention that participants remain alive. |
| Incidence of Adverse Events Related to Treatment | up to 6 months | All adverse events and their relationships to study drugs and procedures will be recorded，to assess overall safety, feasibility and tolerability of treatment. |
| Progression-free Survival (PFS) | up to 2 years | The median length of time from initiation of study drug(s) disease progression as defined by RECIST v1.1, or death. Progressive Disease (PD): ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression. |
| Change in the intestinal microbiome community | up to 6 months | Mean change from baseline of bacterial species compared with 6 months post fecal microbiota transplantation (FMT). |
| Quality of life based on the questionnaire | up to 2 years | The EORTC QLQ-STO22/EORTC QLQ-C30 questionnaire will be used to assess the quality of life of the participants. |
| Change in the immunity | up to 6 months | Mean change from baseline of immune cells compared with 6 months post fecal microbiota transplantation (FMT). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Marker of nutritional status | up to 2 years | Hemoglobin is a measure of the nutritional status and are seen as markers for the catabolic state of cachectic cancer patients. |
| Body Weight | up to 2 years | Body Weight Change. (kilograms) |
| Appetite | up to 2 years | Appetite measured by FAACT |
Countries
China
Contacts
Primary ContactXiangyu Kong, associate professor
Outcome results
None listed